R&D

About

BioCorRx Pharmaceuticals, Inc. is a commercial and clinical stage biotechnology company and a subsidiary of BioCorRx Inc. specializing in developing treatments for substance use disorder.


BioCorRx Pharmaceuticals pipeline

Ongoing Clinical Trials

Pipeline
Program Preclinical Phase 1 Phase 2 Link

BICX104

for Opioid Use Disorder¹
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Click here

BICX104

for Alcohol Use Disorder¹
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Click here

BICX104

for Methamphetamine Use Disorder¹
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
  1. National Institute on Druge Abuse

Overview

BioCorRx Pharmaceuticals is developing BICX104 as its lead asset, an implantable, long-acting naltrexone pellet for treatment of OUD, AUD, and MUD. BICX104 is a sustained, three-month treatment that potentially offers an option for patients suffering from OUD, AUD & MUD and may reduce the rate of non-compliance and relapse.

  • 100% biodegradable
  • Nearly pure naltrexone pellet devoid of polymers
  • 15-minute in office procedure
  • Removeable if needed
  • Solution for non compliance
  • BICX104 is progressing through the clinic via a 505(b)(2) regulatory pathway for OUD/AUD and MUD
  • Received funding from NIH/NIDA (National Institutes of Health and National Institute on Drug Abuse)
  • Received FDA Clearance of Investigational New Drug (IND) application for BICX104 in 2021
  • Phase 1 human trial completed March 22, 2023
  • Results demonstrate sustained delivery of BICX104 over 12 weeks and was generally well tolerated